Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1552W HIGH $6.83
Volume
88.17 K
Value Traded
1.06 M
Short % Float
8.11%
+7.63%Week
-22.4%1 Month
-17.79%3 Month
-3.19%6 Month
-89.15%5 Year
-83.08%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
316.02 M
EPS (TTM)
-0.76
P/E Ratio
-
Ent. Value
164.26 M
Total Shares
79.80 M
Float Shares
44.73 M
Insiders
43.95%
Institutions
44.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PRLD Catalyst Timeline
Dated clinical, regulatory and corporate events for Prelude Therapeutics Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prelude Therapeutics Incorporated
386Total events
6Upcoming
65Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearancePRT13722IND
FDA clearance of IND for PRT13722 in HR+/HER2- breast cancer
HR+/HER2- breast cancersource ↗
●Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
▲First Patient DosedPRT12396Trial
Initiated enrollment of Phase 1 study of PRT12396 in PV and MF
polycythemia vera (PV) and myelofibrosis (MF)source ↗
◆Poster PresentationPRT13722Presentation
Poster presentation of preclinical data for PRT13722 at AACR 2026
HR+/HER2- breast cancersource ↗
▼Equity OfferingCorporate
Pricing of $90.0 million underwritten offering of common stock and pre-funded warrants
◆Oral PresentationPresentation
Educational lecture on degrader-antibody conjugates (DACs) at AACR 2026
◆First Patient DosedPRT12396Trial
First patient dosing anticipated by Q2 2026
polycythemia vera and myelofibrosissource ↗
●Trial InitiationPRT12396Trial
Phase 1 study initiation anticipated by Q2 2026
polycythemia vera and myelofibrosissource ↗
●Trial InitiationTrial
Phase 1 initiation anticipated for JAK2V617F mutant selective JH2 inhibitors
VF+ myeloproliferative neoplasms (MPNs) (MF, PV, ET)source ↗
▲IND ClearancePRT12396IND
FDA clearance of IND for PRT12396
polycythemia vera and myelofibrosissource ↗
●IND SubmissionPRT12396IND
IND filing for PRT12396 expected in Q1 2026
myeloproliferative neoplasmssource ↗
▲Trial InitiationPRT12396Trial
Phase 1 study initiation for PRT12396 expected in Q1 2026
myeloproliferative neoplasmssource ↗
◆IND SubmissionIND
IND filing for JAK2V617F JH2 inhibitor expected in first half of 2026
myeloproliferative neoplasms (MPNs)source ↗
▲Runway Guidance UpdateCorporate
Cash runway into 2026 with $201.9 million as of March 31, 2024
◆Oral PresentationPresentation
Oral presentation of CALR-targeted degrader antibody conjugate (DAC) preclinical data at ASH 2025
CALR-mutated myeloproliferative neoplasmssource ↗
◆Oral PresentationPRT12396Presentation
First disclosure of PRT12396 preclinical data at ASH 2025
myeloproliferative neoplasmssource ↗
●IND Enabling CompletePRT12396Preclinical
GLP toxicology studies completed for PRT12396
myeloproliferative neoplasmssource ↗
◆Oral PresentationPresentation
First disclosure of JAK2V617F JH2 inhibitor program data at ASH 2025
myeloproliferative neoplasmssource ↗
▲Partnership / LicenseCorporate
DAC Discovery Collaboration with AbCellera announced and expanded
Broad utility across multiple indicationssource ↗
▲Partnership / LicenseCorporate
Exclusive option agreement with Incyte for JAK2V617F JH2 inhibitor program
myeloproliferative neoplasmssource ↗
▼Equity OfferingCorporate
Incyte purchases 6.25M shares of Prelude non-voting common stock at $4.00/share
▲Partnership / LicenseCorporate
Exclusive option agreement with Incyte for JAK2V617F inhibitor program announced November 2025
myeloproliferative neoplasmssource ↗
▲Partnership / LicenseCorporate
Amended and expanded DAC collaboration with AbCellera Biologics
◆Enrollment UpdatePRT7732Trial
PRT7732 currently enrolling at seventh dosing cohort (125 mg)
SMARCA4-mutated cancerssource ↗
▼Program DiscontinuationPRT3789Corporate
Pause further development of PRT3789; focus on PRT7732
SMARCA4-mutated cancerssource ↗
◆Oral PresentationPresentation
Prelude Therapeutics to participate in Goldman Sachs 46th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Prelude Therapeutics to participate in Jefferies Global Healthcare Conference 2025 fireside chat
◆Oral PresentationPresentation
Prelude Therapeutics to participate in Citizens Life Sciences Conference fireside chat
▲Enrollment CompletePRT3789Trial
PRT3789 monotherapy dose escalation enrollment completed
SMARCA4-mutated cancerssource ↗
●Poster PresentationPRT3789Presentation
Preclinical data on mechanism of action of PRT3789 presented at AACR 2025
SMARCA4 mutated cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How PRLD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-21 | PRT13722 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$335M
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
1.1x
rNPV / MCap
Top 45%
Micro Cap(rank 297 of 658)
Percentile Rank
Prelude Therapeutics Incorporated faces pipeline headwinds (38/100), with $1.3B risk-adjusted pipeline value, led by PRT1419 in Multiple Myeloma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRT1419 Small moleculeCompletedNCT04543305 | Multiple Myeloma | Phase 1 | COMPLETED | 16 | Mar 21, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRLD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PRT3789 | patients with advanced solid tumors with loss of SMARCA4 | Phase 1/2 | 2025-04-25 | SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4 thereby enhancing the selectivity profile and contributing to the broad therapeutic index and favorable safety profile observed with PRT3789 in clinical studies to date.Read More | Investor Contact: Robert A. Doody, Jr. Senior Vice President, Investor Relations Prelude Therapeutics Incorporated 484.639.7235 rdoody@preludetx.comRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Morris Charles QOfficer (Chief Medical Officer) | Grant/Award | 450,000 450,000 held | $4.70 | 05/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRLD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.4 % (100 %) | 73.15 M | 13.72 M | 25.81% ( 2.82 M) |
PRLD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRLD ranks across every disease it competes in
Competitive Position is a premium feature
See how PRLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRLD News
PRLDPrelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prelude Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. The company's leadership will engage in a fireside chat on September 16, discussing their innovative oncology therapies. A live webcast will be available on their website, with recordings archived for 90 days.
Read more →PRLD▼ -8.3%on this newsshared move
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Prelude Therapeutics has received FDA clearance for its Investigational New Drug application for PRT13722, an oral KAT6A selective degrader aimed at treating HR+/HER2- breast cancer. The Phase 1 study will assess the drug's safety, tolerability, and efficacy. Patient enrollment is expected to begin in Q4 2026, marking a significant step in cancer treatment innovation.
Read more →PRLD▲ +10.1%on this news
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics has announced its financial results for the second quarter of 2026, highlighting the upcoming initiation of a Phase 1 study for PRT13722, an oral KAT6A degrader aimed at treating HR+ breast cancer. The company also presented promising preclinical data at the AACR Annual meeting, showcasing the drug's differentiated profile.
Read more →PRLDPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics has reported its financial results for Q1 2026 and provided updates on its research and development pipeline. The company has initiated enrollment in a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor, and anticipates a mid-2026 IND filing for PRT13722, aimed at ER+ breast cancer treatment. Prelude aims to leverage a substantial cash runway expected to last until mid-2028, signaling a potential for ongoing development despite a reported net loss.
Read more →PRLDPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics has announced the pricing of an underwritten offering, raising approximately $90 million through the sale of shares and pre-funded warrants. The offering, led by RA Capital Management, is expected to close on April 21, 2026. The funds will primarily be used for general corporate purposes, including research and development of its oncology products.
Read more →PRLDPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class KAT6A degrader, at the AACR Annual Meeting 2026. The data indicate its potential for complete tumor regressions in HR+/HER2- breast cancer models, with an improved safety profile. The company plans to file an IND application by mid-2026 and initiate clinical trials in the second half of 2026.
Read more →PRLD▲ +25.5%on this newsshared move
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics has appointed Dr. Charles Morris as Chief Medical Officer, effective April 20, 2026. With over 30 years of oncology drug development experience, Dr. Morris will lead the company's efforts as it advances its clinical programs targeting myeloproliferative neoplasms and ER+ breast cancer, expected to enter clinical development in 2026. His expertise is seen as crucial for the execution of Prelude's innovative cancer therapies, which aim to address significant unmet needs in the patient community.
Read more →PRLD▼ -9%on this news
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics announced that their oral KAT6A selective degrader, PRT13722, has been accepted for presentation at the AACR Annual Meeting 2026. The company aims to demonstrate the drug's potential for treating ER+ breast cancer with improved efficacy and safety. An IND filing is expected mid-2026, with clinical trials planned for later that year.
Read more →PRLD▲ +16.5%on this news
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported its financial results for the full year 2025, highlighting FDA clearance of its Investigational New Drug application for PRT12396 and plans to initiate Phase 1 studies for both PRT12396 and PRT13722 in 2026. The company emphasized its focus on developing mutant-selective inhibitors and KAT6A degraders while maintaining a cash runway expected to last into mid-2027. Despite a net loss of $99.5 million, Prelude believes its innovative approaches could significantly benefit patients with specific cancer targets.
Read more →PRLDPrelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics has received FDA clearance for its Investigational New Drug Application for PRT12396, a mutant-selective JAK2V617F inhibitor. The Phase 1 study is set to begin by Q2 2026, focusing on patients with polycythemia vera and myelofibrosis. This development is seen as a pivotal step in advancing their oncology programs.
Read more →PRLDThis presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited t
Prelude Therapeutics has provided a corporate presentation outlining its forward-looking statements and anticipated developments in its clinical programs. The focus is on two primary candidates targeting the JAK2V617F mutation in myeloproliferative neoplasms and KAT6A selective degraders for breast cancer. The detailed milestones for these programs and the strategic insights from the leadership team highlight the company's commitment to advancing precision medicine. However, no specific negative events were reported in this presentation.
Read more →PRLDPrelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Prelude Therapeutics presented promising preclinical data on its JAK2V617F-selective JH2 inhibitor, PRT12396, at the ASH Annual Meeting. The data suggests potential for disease modification in myeloproliferative neoplasms (MPNs). Additionally, the company disclosed a novel mCALR-targeted degrader antibody conjugate. Prelude plans to file for IND in early 2026, aiming to advance both programs into clinical trials.
Read more →About Prelude Therapeutics Incorporated
Headquarters175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
BIOPHARMAWATCH ELITE PLUS
Trade the next PRLD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime